The Dutch Parelsnoer Institute--Neurodegenerative diseases; methods, design and baseline results
- PMID: 25551191
- PMCID: PMC4301568
- DOI: 10.1186/s12883-014-0254-4
The Dutch Parelsnoer Institute--Neurodegenerative diseases; methods, design and baseline results
Abstract
Background: The Parelsnoer Institute is a collaboration between 8 Dutch University Medical Centers in which clinical data and biomaterials from patients suffering from chronic diseases (so called "Pearls") are collected according to harmonized protocols. The Pearl Neurodegenerative Diseases focuses on the role of biomarkers in the early diagnosis, differential diagnosis and in monitoring the course of neurodegenerative diseases, in particular Alzheimer's disease. The objective of this paper is to describe the design and methods of the Pearl Neurodegenerative Diseases, as well as baseline descriptive variables, including their biomarker profile.
Methods: The Pearl Neurodegenerative Diseases is a 3-year follow-up study of patients referred to a memory clinic with cognitive complaints. At baseline, all patients are subjected to a standardized examination, including clinical data and biobank materials, e.g. blood samples, MRI and cerebrospinal fluid. At present, in total more than 1000 patients have been included, of which cerebrospinal fluid and DNA samples are available of 211 and 661 patients, respectively. First descriptives of a subsample of the data (n = 665) shows that patients are diagnosed with dementia (45%), mild cognitive impairment (31%), and subjective memory complaints (24%).
Discussion: The Pearl Neurodegenerative Diseases is an ongoing large network collecting clinical data and biomaterials of more than 1000 patients with cognitive impairments. The project has started with data analyses of the baseline characteristics and biomarkers, which will be the starting point of future specific research questions that can be answered by this unique dataset.
Similar articles
-
The ROSAS Cohort: A Prospective, Longitudinal Study of Biomarkers for Alzheimer's Disease. Strategy, Methods and Initial Results.J Prev Alzheimers Dis. 2017;4(3):183-193. doi: 10.14283/jpad.2017.8. J Prev Alzheimers Dis. 2017. PMID: 29182709
-
Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.J Alzheimers Dis. 2015;44(2):625-33. doi: 10.3233/JAD-141716. J Alzheimers Dis. 2015. PMID: 25322924
-
[Biomarkers in Alzheimer's disease].Rev Neurol. 2014 Apr 1;58(7):308-17. Rev Neurol. 2014. PMID: 24677154 Review. Spanish.
-
Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060. JAMA Psychiatry. 2014. PMID: 25162367
-
[The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].Rev Neurol (Paris). 2012 Jun;168(6-7):471-82. doi: 10.1016/j.neurol.2011.11.007. Epub 2012 May 12. Rev Neurol (Paris). 2012. PMID: 22579080 Review. French.
Cited by
-
Cerebral blood flow and cognitive functioning in patients with disorders along the heart-brain axis: Cerebral blood flow and the heart-brain axis.Alzheimers Dement (N Y). 2020 May 12;6(1):e12034. doi: 10.1002/trc2.12034. eCollection 2020. Alzheimers Dement (N Y). 2020. PMID: 32995468 Free PMC article.
-
Sex differences in memory clinic patients with possible vascular cognitive impairment.Alzheimers Dement (Amst). 2020 Aug 25;12(1):e12090. doi: 10.1002/dad2.12090. eCollection 2020. Alzheimers Dement (Amst). 2020. PMID: 32875057 Free PMC article.
-
Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer's disease: protocol of the BEAT-IT study.Alzheimers Res Ther. 2019 May 24;11(1):48. doi: 10.1186/s13195-019-0503-2. Alzheimers Res Ther. 2019. PMID: 31122267 Free PMC article.
-
Lower haemoglobin concentrations are associated with impaired cognition in patients with carotid artery occlusion.Cereb Circ Cogn Behav. 2023 Jun 24;5:100169. doi: 10.1016/j.cccb.2023.100169. eCollection 2023. Cereb Circ Cogn Behav. 2023. PMID: 37404564 Free PMC article.
-
Evaluation of a deep learning approach for the segmentation of brain tissues and white matter hyperintensities of presumed vascular origin in MRI.Neuroimage Clin. 2017 Oct 12;17:251-262. doi: 10.1016/j.nicl.2017.10.007. eCollection 2018. Neuroimage Clin. 2017. PMID: 29159042 Free PMC article.
References
-
- International World Health Organization . Dementia: A Public Health Priority. 2012.
-
- McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collertan D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47(5):1113–1124. doi: 10.1212/WNL.47.5.1113. - DOI - PubMed
-
- Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51(6):1546–1554. doi: 10.1212/WNL.51.6.1546. - DOI - PubMed
-
- Jack CR, Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207–216. doi: 10.1016/S1474-4422(12)70291-0. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical